Obesity Is Associated With Invasive Breast Cancer Risk
Amerika Birleşik Devletinde yapılan, Women’s Health Initiative (WHI) clinical çalışmasının sonuçlarına göre
Obesity Is Associated With Invasive Breast Cancer Risk
Amerika Birleşik Devletinde yapılan, Women’s Health Initiative (WHI) clinical çalışmasının sonuçlarına göre
– 67?142 menopoz sonrası kadının dahil edildiği 40 merkezli çalışmanın verilerine göre
– Obez yada aşırı kilolu olan menopoz sonrası kadınlarda meme kanseri riski, normal ağırlıkta olanlara göre daha yüksek olarak saptandı.
– Vücut kitle indeksi 35/kg/m2 üstünde olan kadınlarda, meme kanseri riski 1.58 kat normal ağırlıkta olanlara göre artmış olarak saptandı.
– Aynı zamanda obez olan kadınlarda meme kanseri olanlarda hormon reseptör pozitifliği, daha büyük tümör ve koltuk altı lenf nodlarına metastaz daha fazla oranda saptanmış.
– Aynı zamanda çalışma anında Vücut kitle indeksi 25/kg/m2 altında olan ve vücut ağrırlıkları gözlem peryodu boyunca %5 artan hasatalarda meme kanseri risikinde artma saptanmış
Kaynak: Obesity Is Associated With Invasive Breast Cancer Risk
JAMA Oncol; 2015 Jun 11; EPub Ahead of Print; ML Neuhouser, AK Aragaki, RL Prentice, et al
ABSTRACT
ABSTRACT | INTRODUCTION | METHODS | RESULTS | DISCUSSION | CONCLUSIONS |ARTICLE INFORMATION | REFERENCES
Importance More than two-thirds of US women are overweight or obese, placing them at increased risk for postmenopausal breast cancer.
Objective To investigate in this secondary analysis the associations of overweight and obesity with risk of postmenopausal invasive breast cancer after extended follow-up in the Women’s Health Initiative (WHI) clinical trials.
Design, Setting, and Participants The WHI clinical trial protocol incorporated measured height and weight, baseline and annual or biennial mammography, and adjudicated breast cancer end points in 67?142 postmenopausal women ages 50 to 79 years at 40 US clinical centers. The women were enrolled from 1993 to 1998 with a median of 13 years of follow-up through 2010; 3388 invasive breast cancers were observed.
Main Outcomes and Measures Height and weight were measured at baseline, and weight was measured annually thereafter. Data were collected on demographic characteristics, personal and family medical history, and personal habits (smoking, physical activity). Women underwent annual or biennial mammograms. Breast cancers were verified by medical records reviewed by physician adjudicators.
Results Women who were overweight and obese had an increased invasive breast cancer risk vs women of normal weight. Risk was greatest for obesity grade 2?plus?3 (body mass index [BMI], calculated as weight in kilograms divided by height in meters squared, >35.0) (hazard ratio [HR] for invasive breast cancer, 1.58; 95% CI, 1.40-1.79). A BMI of 35.0 or higher was strongly associated with risk for estrogen receptor–positive and progesterone receptor–positive breast cancers (HR, 1.86; 95% CI, 1.60-2.17) but was not associated with estrogen receptor–negative cancers. Obesity grade 2?plus?3 was also associated with advanced disease, including larger tumor size (HR, 2.12; 95% CI, 1.67-2.69; P?=?.02), positive lymph nodes (HR, 1.89; 95% CI, 1.46-2.45; P?=?.06), regional and/or distant stage (HR, 1.94; 95% CI, 1.52-2.47; P?=?.05), and deaths after breast cancer (HR, 2.11; 95% CI, 1.57-2.84; P?
Conclusions and Relevance Obesity is associated with increased invasive breast cancer risk in postmenopausal women. These clinically meaningful findings should motivate programs for obesity
Original Investigation | June 11, 2015
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer RiskA Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trials FREE ONLINE FIRST
Marian L. Neuhouser, PhD, RD1; Aaron K. Aragaki, MS1; Ross L. Prentice, PhD1; JoAnn E. Manson, MD, MPH, DrPH2; Rowan Chlebowski, MD, PhD3; Cara L. Carty, PhD4; Heather M. Ochs-Balcom, PhD5; Cynthia A. Thomson, PhD, RD6; Bette J. Caan, DrPH7; Lesley F. Tinker, PhD, RD1; Rachel Peragallo Urrutia, MD8; Jennifer Knudtson, MD9; Garnet L. Anderson, PhD1
[+] Author Affiliations
JAMA Oncol. Published online June 11, 2015. doi:10.1001/jamaoncol.2015.1546
